Dharmesh Kant, Head Research at Chola Securities, outlined a mixed sector view. He expects a temporary impact on InterGlobe Aviation due to fuel costs...
Dharmesh Kant, Head of Research at Chola Securities, said Sun Pharma’s all-cash acquisition of Organon could improve return ratios and support valuations, but may...
Dharmesh Kant, Head of Research at Chola Securities, says markets offer selective opportunities across sectors. From a long-term perspective, he prefers IndusInd Bank, followed...
Trent’s recent quarterly performance shows steady revenue growth but may signal a shift to a lower growth range going forward, according to Dharmesh Kant,...